Hemgenix (Etranacogene Dezaparvovec)

Hemgenix is prescribed for patients with hemophilia B to provide a long‑term therapeutic option. It is used in clinical practice to:

• Reduce the frequency of spontaneous bleeding events.
• Decrease reliance on regular factor IX replacement infusions.
• Improve overall quality of life for individuals with moderate to severe hemophilia B.
• Offer a potentially durable solution through a single administration.
• Complement existing hemophilia B management strategies when appropriate.

Common side effects of Hemgenix are generally mild and may include:

• Transient elevation of liver enzymes.
• Low‑grade fever or flu‑like symptoms.
• Injection site reactions such as redness or swelling.
• Nausea or mild gastrointestinal discomfort.

Serious side effects, although less frequent, require medical attention:

• Severe liver inflammation or hepatitis.
• Immune reactions to the viral vector.
• Thrombotic events or clot formation.
• Development of inhibitors against factor IX.
• Unexplained bleeding despite therapy.

Before initiating Hemgenix therapy, several precautions should be considered:

• Assess baseline liver function and monitor regularly during treatment.
• Evaluate for pre‑existing antibodies to adeno‑associated viruses.
• Discuss potential risks with patients who have a history of severe allergic reactions.
• Use caution in individuals with active infections or immunocompromised status.
• Counsel women of childbearing potential about unknown pregnancy safety data.
• Ensure appropriate follow‑up for long‑term safety monitoring.

Hemgenix may interact with other medications or therapies as follows:

Avoid

• Concurrent use of strong immunosuppressants that could diminish vector efficacy.
• Live vaccines administered shortly before or after gene therapy.

Use with caution

• Anticoagulants or antiplatelet agents, due to altered bleeding risk.
• Other factor IX replacement products, which may affect dosing assessments.
• Medications known to affect liver enzymes, requiring closer hepatic monitoring.
• Experimental gene‑editing agents, pending further safety data.